{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:23:05Z","timestamp":1793906585488,"version":"4.8.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoanabolic-first treatment sequences are superior to oral bisphosphonates for fracture reduction and bone mineral density (BMD) gain. However, data comparing osteoanabolic medications, with the more potent antiresorptive, denosumab (DMAb), are limited. We analyzed FRAME and FRAME Extension data to assess BMD and fracture incidence in patients treated with romosozumab (Romo) followed by DMAb (Romo\/DMAb) versus DMAb (DMAb\/DMAb) for 24\u00a0months. In FRAME, women aged \u226555\u00a0years (total hip [TH] or femoral neck [FN] T-score: \u20132.5 to \u20133.5) were randomized to Romo or placebo for 12\u00a0months followed by DMAb for 12\u00a0months. In FRAME Extension, both cohorts received DMAb for another 12\u00a0months. This post hoc analysis compared BMD change and fracture incidence in patients on Romo\/DMAb (months 0\u201324) versus DMAb\/DMAb (months 12\u201336). Patient characteristics were balanced by propensity score weighting (PSW) and sensitivity analyses were conducted using PSW with multiple imputation (PSW-MI) and propensity score matching (PSM). Unmeasured confounding was addressed using E-values. After PSW, over 24\u00a0months, compared with DMAb\/DMAb, treatment with Romo\/DMAb produced significantly greater BMD increases at the lumbar spine [LS], TH, and FN (mean differences: 9.3%, 4.4%, and 4.1%, respectively; all p&amp;lt;0.001). At month 24, in women with a baseline T-score of \u20133.0, the probability of achieving a T-score\u2009&amp;gt;\u2009\u20132.5 was higher with Romo\/DMAb versus DMAb\/DMAb (LS: 92% versus 47%; TH: 50% versus 5%). In the Romo\/DMAb versus DMAb\/DMAb cohorts, new vertebral fractures were significantly reduced (0.62% versus 1.26% [odds ratio\u2009=\u20090.45; p=0.003]) and rates of clinical, nonvertebral, and hip fractures were lower (differences not significant). Similar BMD and fracture outcomes were observed with PSW-MI and PSM sensitivity analyses. The sequence of Romo\/DMAb resulted in greater BMD gains and higher probability of achieving T-scores &amp;gt; \u20132.5, significantly reduced new vertebral fracture incidence, and numerically lowered the incidence (not significant) of clinical, nonvertebral, and hip fractures versus DMAb only through 24\u00a0months.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae116","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:33:47Z","timestamp":1721648027000},"page":"1268-1277","source":"Crossref","is-referenced-by-count":25,"title":["Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University College of Physicians and Surgeons , New York, NY 10032 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Oates","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA 91230 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Betah","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA 91230 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Timoshanko","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough SL1 3WE , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-7240","authenticated-orcid":false,"given":"Zhenxun","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA 91230 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva , CH-1211 Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"McClung","sequence":"additional","affiliation":[{"name":"Oregon Osteoporosis Center , Portland, OR 97225 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"Suppl 1","key":"2024090404563834100_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal psteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"2024090404563834100_ref2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024090404563834100_ref3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"issue":"10","key":"2024090404563834100_ref4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"10117","key":"2024090404563834100_ref5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"2024090404563834100_ref6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2024090404563834100_ref7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis","volume":"105","author":"Leder","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024090404563834100_ref8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4158\/EP-2019-0596","article-title":"Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture","volume":"26","author":"Cosman","year":"2020","journal-title":"Endocr Pract"},{"issue":"6","key":"2024090404563834100_ref9","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024090404563834100_ref10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2024090404563834100_ref11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024090404563834100_ref12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2024090404563834100_ref13","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024090404563834100_ref14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"key":"2024090404563834100_ref15","volume-title":"EVENITY\u00ae (Romosozumab-Aqqg) US Prescribing Information","year":"2019"},{"issue":"5","key":"2024090404563834100_ref16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024090404563834100_ref17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024090404563834100_ref18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2024090404563834100_ref19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024090404563834100_ref20","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10546","article-title":"Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals","volume":"5","author":"Cosman","year":"2021","journal-title":"JBMR Plus"},{"issue":"30","key":"2024090404563834100_ref21","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"2024090404563834100_ref22","article-title":"A unified approach to measuring the effect size between two groups using SAS\u00ae","author":"Yang"},{"issue":"4","key":"2024090404563834100_ref23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2024090404563834100_ref24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024090404563834100_ref25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"issue":"3","key":"2024090404563834100_ref26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"7","key":"2024090404563834100_ref27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"2024090404563834100_ref28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"2024090404563834100_ref29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2024090404563834100_ref30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.4433","article-title":"Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project","volume":"37","author":"Eastell","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024090404563834100_ref31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbmr.1854","article-title":"Goal-directed treatment of osteoporosis","volume":"28","author":"Cummings","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"20","key":"2024090404563834100_ref32","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"2024090404563834100_ref33","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"2024090404563834100_ref34","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"},{"issue":"1","key":"2024090404563834100_ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"issue":"S1","key":"2024090404563834100_ref36","first-page":"S1","article-title":"Probability of achieving bone mineral density treatment goals with denosumab treatment in women with osteoporosis. 2022 Annual Meeting of the American Society for Bone and Mineral Research. Austin, Texas, USA. September 09\u201312, 2022","volume":"38","author":"Cosman","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024090404563834100_ref37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"S1","key":"2024090404563834100_ref38","article-title":"Romosozumab efficacy in postmenopausal women without prior fracture who fulfill AACE criteria for osteoanabolic therapy: post-hoc analysis of clinical trial data","volume":"38","author":"McClung","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3\/4","key":"2024090404563834100_ref39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcome Res Methodol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae116\/58932513\/zjae116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1268\/58994099\/zjae116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1268\/58994099\/zjae116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T07:27:29Z","timestamp":1725434849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/9\/1268\/7718517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae116","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,23]]}}}